Current Coverage Archives

Eli Lilly’s $5 Billion U.S. Manufacturing Bet: What It Means for Pharma and LLY Stock in 2025 ( $LLY $SPY $IBB )

by John F. Heerdink, Jr. September 16, 2025 505Views 0Likes

Eli Lilly’s announcement of a $5 billion investment in manufacturing marks another chapter in the pharmaceutical giant’s escalating commitment to U.S. production infrastructure—a move emblematic of the sector’s race to harness domestic capacity and innovation amid ongoing global uncertainty and rising demand…

Biotech Breakthrough: Serina Therapeutics Secures Insider Led Financing for SER-252 Registrational Trial in Neurology Pipeline – ( $SER $BHVN $XBI )

by John F. Heerdink, Jr. September 10, 2025 551Views 0Likes

Serina Therapeutics (NYSE American: SER), a biotechnology firm headquartered at the HudsonAlpha Institute in Huntsville, Alabama, has rapidly advanced its position in the neurology pipeline by leveraging its proprietary POZ Platform™. Over the past several months, the company has unveiled a series…

The InterGroup Corporation’s Hilton SF Stake Puts It at the Heart of San Francisco’s AI-Driven Revival – ( $AAPL $INTG $NVDA )

by John F. Heerdink, Jr. September 9, 2025 433Views 0Likes

The InterGroup Corporation (NASDAQ: INTG) is emerging as a compelling turnaround story in 2025, combining solid real estate assets with a strategic push to unlock shareholder value and capitalize on market dislocations. Recent Highlights and Stock Momentum In August, InterGroup’s (INTG) shares…

Serina Therapeutics (SER): How Steven Ledger’s Vision is Seeking to Transform Parkinson’s Treatment With Weekly Injections

by John F. Heerdink, Jr. September 3, 2025 422Views 0Likes

Serina Therapeutics (NYSE American: SER) is standing out in the biotech world for its push to simplify Parkinson’s care, moving from several daily pills to a once-weekly injection—a mission led by CEO Steven Ledger, who appears front and center in the company’s…

Global Central Banks Drive Gold to New Record, Surpassing U.S. Bonds in Portfolios – ( $GLD $SPY )

by John F. Heerdink, Jr. September 2, 2025 354Views 0Likes

Gold has achieved a historic milestone in 2025, with central banks now holding more gold in their reserves than U.S. Treasuries for the first time since 1996—a shift signaling profound changes in global finance and monetary management. Central Banks Shift to Gold…

Beyond Daily Pills: Eupraxia’s Annual Therapy Could Revolutionize Eosinophilic Esophagitis Management – ( $EPRX $IBB $XBI )

by John F. Heerdink, Jr. September 2, 2025 551Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) is defining a new frontier in the treatment of eosinophilic esophagitis (EoE) with its innovative candidate, EP-104GI. This investigational therapy, developed with Eupraxia’s proprietary DiffuSphere™ technology, delivers long-lasting and locally targeted steroid treatment directly into the esophageal wall—offering…

Eupraxia Pharmaceuticals (NASDAQ: EPRX) Accelerates Toward Key Clinical Milestones—Wall Street Remains Bullish

by John F. Heerdink, Jr. August 28, 2025 630Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) has recently achieved several pivotal milestones, signaling increased momentum in its late-stage clinical programs and drawing strong endorsements from Wall Street analysts, while shares of Eupraxia have risen ~100% over the last 12 months. The company’s clinical progress,…

Parkinson’s Drug Milestone: Serina Therapeutics Wins FDA Support, HCW Wainwright Reaffirms Buy Rating on SER Stock ( $SER $IBB $XBI )

by John F. Heerdink, Jr. August 28, 2025 621Views 0Likes

HCW Wainwright has reiterated its Buy rating on Serina Therapeutics (NYSE American: SER), emphasizing both the company’s clinical progress and robust valuation metrics as key drivers for investor optimism. Company Snapshot and Market Performance Serina Therapeutics (SER) currently trades at $5.04 per share with a market…

How MongoDB’s Product Innovations and AI Partnerships Are Fueling a Bullish Outlook ( $MDB $QQQ )

by John F. Heerdink, Jr. August 27, 2025 469Views 0Likes

MongoDB, Inc. (MDB) is riding a wave of momentum, decisively positioning itself as a foundational enabler of the artificial intelligence revolution with robust financials, rapid customer growth, and strategic innovation initiatives. Over the past several months, a steady cadence of announcements—ranging from…

AT&T’s $23 Billion EchoStar Spectrum Deal: What It Means for 5G, Broadband, and U.S. Wireless Competition – ( $SATS $T )

by John F. Heerdink, Jr. August 27, 2025 613Views 0Likes

AT&T (T) struck a $23 billion deal this week to acquire wireless spectrum licenses from EchoStar(SATS), a move set to significantly bolster its holdings across more than 400 U.S. markets and intensify the telecom arms race nationwide. The all-cash transaction, announced Tuesday,…

Current Coverage

Your Guide To Staying Informed In The Markets